Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation

Bárbara Lima; Miguel Henriques Abreu; Susana Sousa; Carla Bartosch; Deolinda Pereira

doi:10.1016/j.gore.2022.100942

Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation

Gynecol Oncol Rep. 2022 Feb 23:40:100942. doi: 10.1016/j.gore.2022.100942. eCollection 2022 Apr.

Authors

Bárbara Lima¹, Miguel Henriques Abreu², Susana Sousa², Carla Bartosch³, Deolinda Pereira²

Affiliations

¹ Department of Medical Oncology, Hospital Senhora da Oliveira, Guimarães, Portugal.
² Department of Medical Oncology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
³ Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.

Abstract

Low-grade serous ovarian cancer (LGSOC) is now considered a different entity from high-grade serous ovarian cancer. The chemoresistance inherent to this type of ovarian cancer narrows the therapeutic options, especially in the recurrent setting. It is thought that the mitogen-activated protein kinase (MAPK) pathway plays a significant role in the pathogenesis of these tumours, and about 2 to 20% of LGSOC harbour a BRAF mutation. Here we present a case report of two patients with a BRAF V600E mutation that achieved sustained clinical responses with combination treatment with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor).

Keywords: BRAF mutation; Combination treatment; Dabrafenib; Low-grade serous ovarian cancer; Trametinib.

Publication types

Case Reports